AstraZeneca

News

AstraZeneca to present the latest cardiovascular research

AstraZeneca and MedImmune will present new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio for the treatment of patients with overlapping diseases and multiple risk fact

News

AZ considers options as US gout drug deal backfires

Ironwood tears up licensing agreement after sales disappoint

News

Neurofibromatosis treatment granted orphan status by EMA

AstraZeneca and Merck & Co.

News

Sanofi stockpiles drugs in case of no-deal Brexit

Fears of border delays and complications in a post-Brexit UK have led to the French pharmaceutical company increasing its contingency stockpiles by four weeks to enable a 14-week supply of

News

AZ pledges to keep prices down, as new drug sales mount

Cancer drug Tagrisso leads the recovery

News

Out with the old… AZ sells European rights to Atacand

AstraZeneca is selling off European commercial rights to its high blood pressure drug Atacand to German biotech Cheplapharm, securing $200 million for “company’s new wave of medicines”.

AstraZeneca to present the latest cardiovascular research

AZ considers options as US gout drug deal backfires

Neurofibromatosis treatment granted orphan status by EMA

Sanofi stockpiles drugs in case of no-deal Brexit

AZ pledges to keep prices down, as new drug sales mount

Out with the old… AZ sells European rights to Atacand

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks